Navigation Links
Rigel Earns Milestone Payments From AstraZeneca
Date:9/29/2010

une inflammatory disease that causes damage to the joints and other organs. It is a major cause of disability, affecting approximately 1 in 100 people, and is also associated with reduced life expectancy, especially if not adequately treated.

Fostamatinib, which has completed a comprehensive phase 2 program, is the first oral spleen tyrosine kinase (syk) inhibitor in development as a novel therapeutic approach for RA. Inhibiting syk is thought to block signaling in multiple cell types involved in inflammation and tissue degradation in RA.   Inhibition of syk signaling is therefore believed to be a very attractive research approach to RA treatment.

About Rigel Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune disorders, as well as muscle and metabolic diseases. Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market its product candidates. Current product development programs include fostamatinib (R788), an oral syk inhibitor that has started its phase 3 clinical trial program for rheumatoid arthritis, and R343, an inhaled syk inhibitor that is in clinical trials for asthma.

Rigel Forward-Looking StatementsThis press release contains "forward-looking" statements, including, without limitation, statements related to the scope of the phase 3 clinical program of R788 (fostamatinib) and the filing of new drug applications, including the timing thereof. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "expected", "believed" and similar expressions are intended to identify these forward-looking statements. These forward-looking stateme
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Rigel to Host Update Conference Call
2. Rigel Announces Third Quarter 2008 Financial Results and Clinical Update
3. Rigel to Present at the 2008 Credit Suisse Healthcare Conference
4. Rigel to Host Conference Call to Discuss Phase 2 Study Results of R788 in Lymphoma Presented at ASH
5. Rigel to Participate at the RBC Capital Markets Healthcare Conference
6. Rigel to Present at Citis Biotech Day
7. Rigel Announces First Quarter 2009 Financial Results
8. Rigel Announces Pricing of Public Offering of 13,000,000 Shares of Common Stock
9. Aerospace engineer earns Oak Ridge Associated Universities Ralph Powe Junior Faculty Award
10. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
11. Advanced Pest Control Earns Quality Pro Designation for General Pest Control Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... August 29, 2014 Three Lawrence ... 2014 Hydrogen Production R&D Award for ... splitting water using sunlight. , Shared with collaborators ... the University of Nevada, Las Vegas (UNLV), the ... models of photoelectrochemical solar-hydrogen production and corrosion processes. ...
(Date:8/29/2014)... 29, 2014 A major challenge before ... start-up dense realm of Boston-Cambridge, is gaining visibility that ... James Sherley, the Director of Boston’s Adult Stem Cell ... and national visibility of his company an important priority ... In addition to a social media marketing campaign ...
(Date:8/28/2014)... USA (PRWEB) August 28, 2014 SPIE ... of Physics and Optical Science and Director of the ... of North Carolina at Charlotte, and co-founder and Chairman ... to serve as the 2015 Vice President of SPIE, ... 2014 President Philip Stahl announced recent election results at ...
(Date:8/28/2014)... August 28, 2014 Best Sanitizers, Inc., ... an alcohol-based hand sanitizer, asks food processors and food ... the hand sanitizer they’re currently using to Best Sanitizers’ ... hygiene is critical to fighting cross-contamination and the spread ... Sanitizers believes there are key criteria that make a ...
Breaking Biology Technology:Livermore Team Awarded for Hydrogen Production Research 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 3The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 4Glenn Boreman, UNC Professor and Plasmonics Co-Founder, Elected to SPIE Presidential Chain 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 3
... (Nasdaq: NPSP ) announced today that it ... decision whether to,proceed with ex-U.S. development and commercialization ... expects to receive,notification from Nycomed at the end ... NPS on the development of GATTEX(TM) (teduglutide),outside North ...
... presented at AACR-NCI-EORTC International Conference on ... and Cancer Therapeutics in San Francisco, ... Zentaris Inc.,(TSX: AEZ; Nasdaq: AEZS), a global ... today presented an abstract outlining novel,data generated ...
... antibody uses novel approach to "de-cloak" cancers -, ... Inc., (TSX:,ARI), a biotechnology company discovering and developing ... new findings have been,presented from its Trop-2 and ... Trop-2 and CD59 abstracts at the AACR press,conference ...
Cached Biology Technology:NPS Pharmaceuticals to Report Third Quarter 2007 Financial Results and Nycomed Decision on GATTEX(TM) Partnership on November 1, 2007 2AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment 2AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment 3AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment 4Arius announces new findings in Trop-2 and CD59 CANCER antibody programs 2Arius announces new findings in Trop-2 and CD59 CANCER antibody programs 3
(Date:9/1/2014)... Is television making us fat? An increasing amount of ... food consumption and a more sedentary lifestyle. Now, a ... TV is alike. Some TV programs might lead people ... find that if you,re watching an action movie while ... Aner Tal, Ph.D. lead author on the new article ...
(Date:9/1/2014)... birth, every child in the U.S. undergoes a battery ... including sickle cell disease. Thousands of children born in ... suffer and die from the disease each year. ... at least some of those deaths. , A ... the lab of George Whitesides, the Woodford L. and ...
(Date:9/1/2014)... As nocturnal animals, bats are perfectly adapted to a life ... between the reflected echoes to measure distance to obstacles or ... different echo delays. A study carried out by researchers at ... that this map dynamically adapts to external factors. , ... bat flies in too close to an object, the number ...
Breaking Biology News(10 mins):Can action movies make you fat? 2Faster, cheaper tests for sickle cell 2Faster, cheaper tests for sickle cell 3Zooming in for a safe flight 2
... Sciences, The Pennsylvania State University, State College, Pennsylvania, 12-15 August ... 2012 -- The Society for the Study of Reproduction ... the 45th SSR Annual Meeting to be held in State ... are to be found on the SSR Meeting page ...
... is available in Spanish . The upsurge ... and affects crops in particular. However, Anabel Robredo, a biologist at ... the case of barley at least, climate change itself is providing ... change is in fact also responsible for a considerable increase in ...
... ANGELES (Jan. 25, 2012) The evolutionary processes ... debate. John Torday, Ph.D., a lead investigator ... has recently co-authored a book entitled Evolutionary Biology, ... biology into evolutionary biology. Rather than focusing ...
Cached Biology News:Barley adapts to climate change 2Barley adapts to climate change 3LA BioMed's Dr. John Torday examines evolution from a cellular perspective 2
... The H2OBIT™ is a fully licensed, high throughput, ... processing of up to 24 microplates. This equates ... plates. A robotic arm rapidly transfers ... resulting in temperature ramping times that are considerably ...
... ONE Ribonuclease is a 27kDa periplasmic enzyme ... of RNA to cyclic nucleotide monophosphate (NMP) ... of these intermediates to 3-NMPs (1). RNase ... known RNases that can cleave a phosophodiester ...
Porcine Pulmonary Artery Endothelial Cells (PPAEC) (>500,000 cells)...
...
Biology Products: